{"disease":{"id":"chronic-infantile-neurological-cutaneous-and-articular-syndrome","name":"Chronic infantile neurological, cutaneous and articular syndrome","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"kineret","indication_name":"Chronic infantile neurological, cutaneous and articular syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anakinra","generic_name":"Kineret","company_name":"Biovitrum Ab","drug_phase":"marketed","molecular_target":"Interleukin-1 receptor, type I","drug_class":"Interleukin-1 Receptor Antagonist","quality_score":41,"revenue":null,"mechanism":""},{"drug_id":"anakinra","indication_name":"Chronic infantile neurological, cutaneous and articular syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kineret","generic_name":"ANAKINRA","company_name":"Biovitrum Ab","drug_phase":"marketed","molecular_target":"Interleukin-1 receptor, type I","drug_class":"Interleukin-1 Receptor Antagonist [EPC]","quality_score":70,"revenue":null,"mechanism":"Kineret blocks the action of interleukin-1, a protein that promotes inflammation."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}